12:00 AM
Jan 04, 2010
 |  BioCentury  |  Finance

Restructuring watch

Restructuring watch

Date Company Staff cuts Cash Years cash pre-cut Cash date Oper loss for 9 mos ended 9/30
10/28/09 SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) 17% to 34 $34.6 2.60 9/30/09 $10.0
Cuts primarily in R&D; discontinued a Phase II trial of RP101, a small molecule that binds to heat shock protein 27 (Hsp27) to treat advanced pancreatic cancer, based on the recommendation of an independent DSMC
10/29/09 Amicus Therapeutics Inc. (NASDAQ:FOLD) 21% to 99 $89.3 1.66 9/30/09 $40.3
Cuts are companywide; will focus on developing Amigal migalastat, a small molecule that enhances alpha galactosidase A activity in Phase III testing for Fabry's disease,...

Read the full 733 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >